Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascentage Pharma Group International ( (HK:6855) ) has provided an announcement.
Ascentage Pharma shareholders approved all resolutions at the 2026 annual general meeting, including adoption of the 2025 audited financial statements, re-election of several non-executive and independent directors, authorization for the board to set director remuneration, and reappointment of Ernst & Young as auditor. Investors also backed a general mandate allowing the board to issue up to 20% of the company’s share capital and endorsed grants of RSUs and options to senior executives, with related parties abstaining, reinforcing compliance with Hong Kong listing rules and supporting the company’s capital flexibility and executive incentive schemes.
The resolutions concerning proposed grants of RSUs and options to chief executive Dr. Yang Dajun and chief medical officer and substantial shareholder Dr. Zhai Yifan were passed after independent shareholders voted, while the executives and core connected persons abstained as required. The broad support for these measures signals continued shareholder confidence in the current leadership and governance framework, and it provides Ascentage Pharma with additional tools to align management incentives and finance future growth through potential equity issuance.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing innovative oncology therapies and operates as a listed company on the Hong Kong Stock Exchange. The firm’s governance structure includes a board of directors and independent non-executive directors, and it relies on equity-based incentives such as RSUs and share options for key executives and shareholders.
Average Trading Volume: 2,379,310
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.91B
See more data about 6855 stock on TipRanks’ Stock Analysis page.